February 2nd 2023
New York City has ended their mpox outbreak after months of successful community outreach and vaccination campaigns.
January 30th 2023
These diseases, exacerbated by poor water quality, sanitation, and health care access, are highlighted today.
December 28th 2022
Changes in microbiology and antimicrobial resistance patterns warrant reevaluation of our current therapies for this condition.
June 8th 2022
A recent study in the United Kingdom suggests that more research into the possible benefits of antiviral drug tecovirimat for treating monkeypox may be warranted after showing positive results in one patient.
June 2nd 2022
Community transmission of monkeypox outside traditional endemic regions of the virus prompts calls for increased vigilance.
IDSA Explains Current State of Monkeypox in the US
At a media briefing this morning, Infectious Diseases Society of America (IDSA) experts discussed the worldwide 600 confirmed cases of monkeypox.
FDA Cites Manufacturing Deficiencies in Second Complete Response Letter for Verrica’s VP-102
Verrica received a Complete Response Letter from the FDA regarding their New Drug Application for the topical molluscum contagiosum treatment, VP-102.
In These COVID 19 Times, Can We Reduce Hospitalizations Due to Skin Infections?
Shortages of health care workers and an increase in COVID-19 cases has put a severe strain on the health care system. Thus, the opportunity to reduce the hospitalizations for other conditions and expand outpatient treatment opportunities should be welcomed.
Risk of Guillain-Barre Syndrome Higher with Recombinant Zoster Vaccine Shingrix
A case series observation study found a slightly higher risk of Guillain-Barre syndrome among Medicare beneficiaries within 42 days after receiving the recombinant zoster vaccine Shingrix, but no changes are needed to guidance recommending the vaccine, investigators said.
FDA Approves Vaccine to Prevent Shingles in Immunocompromised Adults
This approval of the non-live, recombinant sub-unit adjuvanted vaccine, Shingrix, is for the prevention of shingles in adults aged 18 years and older with increased risk of immunodeficiency or immunosuppression.
FDA Approves Dalbavancin
This therapy becomes the first single-dose infusion to treat acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth.
Measles Deaths Increase Significantly
CDC and WHO Data shows a 50% increase worldwide from 3 years ago.
Fosmanogepix Shows Promise as an Effective Novel Antifungal in POC Trial
“The compound appears to be safe and well-tolerated, [and we observed] excellent efficacy based on a very small sample size,” Peter G. Pappas, MD, said.
Enterovirus A71 Outbreak in Colorado Underscores Need for Better Surveillance
A closer look at the 2018 enterovirus A71 outbreak in Colorado highlights the need for non-sterile site testing to detect infections.
Treating Parents Colonized With Staph Aureus Cuts NICU Transmission Risk
Treating parents colonized with S aureus reduced neonatal colonization with concordant S aureus strains when compared to placebo.
The Burden of MRSA and S aureus in Nursing Homes
How many nursing homes have these microbes?
Global Fight Against Measles Slides Backward Since 2016
Global efforts to eliminate measles took a step backward, with the number of cases rising to 353,236 in 2018, up 167% from 132,413 cases in 2016.
Measles Infection Causes "Immune Amnesia" by Attacking Antibodies
Measles infection leaves patients vulnerable to a wide range of other pathogens by destroying antibodies for months or even years, according to a new study.
Single Dose Oritavancin May Lower 30-Day SSTI Hospital Admission Rates
Treating patients who have skin and soft tissue infections with a single dose of oritavancin may lower hospital admission rates compared to vancomycin, at a similar cost.
Enterovirus Antibodies Found in Spinal Fluid of Dozens of AFM Patients
New research found enterovirus antibodies in dozens of patients diagnosed with AFM and ruled out other viruses, offering more insight into the cause of the mysterious polio-like illness.
Contact Precautions in Long-Term VA Facilities Don't Cut MRSA Infections, Study Shows
Although use of gowns and gloves in targeted settings may still be helpful in preventing health care-associated infections, contact precaution policies in VA long-term care facilities had no impact on MRSA acquisition.
IDWeek 2019 News Network: Reducing Cost for CABP and Exploring New Agents
IDWeek2019 News Network: Preventing Readmissions for ABSSSI
IDWeek2019 News Network: Urgent Areas of Unmet Need in ABSSSI
IDWeek 2019 News Network: Current Treatment Landscape for Pneumonia
IDWeek 2019 News Network: How to Cut Down on ABSSSI Readmission Rates
IDWeek 2019 News Network: The Challenges of Treating ABSSSI
United States Maintains Measles Elimination Status Despite Record Year
The announcement came just 1 day after health officials in New York State declared the end of the Rockland County measles outbreak.
Examining the 2018-19 New York State Measles Outbreaks
Two late breaker abstracts at IDWeek 2019 provide an in-depth analysis of the 2018-19 measles outbreaks in the state of New York.
No New Measles Cases Documented Last Week in United States
According to the CDC, there were no new cases of measles reported during the week of September 6-12, 2019.
OASIS Pooled Results: Omadacycline Safe and Efficacious in IVDU and non-IVDU
Investigators have presented the microbiological, efficacy, and safety results in the pooled intravenous drug use vs non-intravenous drug use patients in 2 phase 3 ABSSSI studies, OASIS-1 and 2.
Study Reveals Gaps in Mumps Immunity Among Vaccinated Individuals
A new study of college-aged individuals demonstrated insufficient immunity in a fraction of participants who were vaccinated against mumps in childhood.
4 European Countries Lose Measles Elimination Status
The European Regional Verification Commission for Measles and Rubella Elimination concluded that Albania, Czechia, Greece, and the United Kingdom have lost ground in the fight to eradicate measles.
Comparing Effectiveness of Agents for MSSA Bacteremia
Evidence demonstrates that antimicrobial therapy with an anti-staphylococcal β-lactam antibiotic is the gold standard for treatment of SAB caused by MSSA, but confusion about which agent—particularly cefazolin versus an anti-staphylococcal penicillin—is preferred remains an unanswered question
Essential Vaccines by Age Group
As outbreaks of vaccine-preventable diseases grow, it is important to review vaccination recommendations by age group.
2 Clarke Drive Cranbury, NJ 08512